ACTRN12626000947303进行中（未招募）2 期
A Phase 2a Open-Label, Multicenter, First-in-Human Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDB-1829 in Combination with Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer(mCRPC)
Interdict Bio0 个研究点目标入组 6 人开始时间: 2027年4月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 No limit（—）
- 性别
- Male
入选标准
- •Age 18 or older
- •Confirmed diagnosis of prostate cancer (adenocarcinoma) that has spread to other parts of the body(metastatic disease)
- •Cancer has stopped responding to hormone therapy (castration-resistant prostate cancer, or mCRPC)
- •Currently on hormone therapy (androgen deprivation therapy) or has had surgical removal of thetesticles, with testosterone levels at or below 50 ng/dL
- •Cancer has gotten worse on or after the most recent treatment
- •Able to carry out normal daily activities with little or no physical limitation (ECOG performance status 0 or1)
- •Has not received any prior treatment for mCRPC
排除标准
- •Received chemotherapy, immunotherapy, targeted therapy, or another investigational cancer treatmentwithin 21 days before starting study treatment (or within 6 weeks for prior radiopharmaceutical therapysuch as lutetium-177 PSMA)
- •Received radiation therapy within 28 days before starting study treatment
- •Prostate cancer with small cell or neuroendocrine features on any prior or current biopsy
- •Stroke or mini-stroke (TIA) within the past 6 months
- •History of organ transplant
研究者
相似试验
已完成
1 期
A Phase 1 Multicenter, Open Label, First-in-Human Dose Escalation Study of AFM28, a Bispecific ICE® that Targets CD123 and CD16A, in patients with CD123-Positive Relapsed/Refractory Acute Myeloid Leukemia2023-510021-16-00Affimed GmbH60
招募中
不适用
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer (CINR731A12101)Metastatic Castration-resistant Prostate Cancer (mCRPC)jRCT20312603054
尚未招募
不适用
First-Time-in-Human Study of GSK5471713 in Adults With mCRPCMetastatic Castration Resistant Prostate CancerjRCT203125073254
招募中
不适用
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (PAnTHA)metastatic castration-resistant prostate cancerjRCT20312602693
招募中
不适用
First-in-Human Trial of DS1025a in Participants with Advanced Solid TumorsAdvanced Solid Tumor, Metastatic Solid Tumor, Unresectable Solid TumorjRCT203126032045